Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia

Summary

The purpose of this expanded access study is to be able to provide treatment with HBOC-201 to patients with life-threatening anemia for whom blood is not an option. HBOC-201 is not FDA approved for use in the United States, but is approved as an oxygen carrier in South Africa and Russia.

Timeline

Start

2013-10

Primary completion

2026-10

Completion

2026-12

Drugs

Indications